The Prince Of Darkness's Shadow Phone: Mandelson's Refusal Exposes Starmer's Transparency Farce Peter Mandelson spent much of the past four decades at the center of British power : New Labour architect, Blair-era fixer, former cabinet minister, lobbyist, peer, and one of Westminster's most notorious survivors. Oh, and he was sliding Jeffrey Epstein actionable inside info. His old nickname, the "Prince of Darkness," was never subtle . It captured both his political skill and the suspicion that Mandelson was most comfortable operating where influence, money, and private access overlap. Today, Ministers released more than 1,500 pages - three bulging volumes of emails, handwritten notes, and more than 160 pages of WhatsApps - in what they billed as "unprecedented transparency" over Mandelson's disastrous stint as Britain's ambassador to Washington. And of course, guess what: Mandelson flat-out refused to hand over his personal phone, and that's pretty much that . Cabinet Office solicitors formally requested access on March 31; he declined to comply. The government admitted it had "no further recourse." MP David Davis called this a "National Security Issue." So the twice disgraced, Epstein-tainted, and forever scheming – was handed one of Britain's most sensitive diplomatic jobs despite flashing red lights. Now, even as Keir Starmer's government tries to publish its way out of scandal, the most important communications may remain exactly where Mandelson wants them: out of sight. Vetting Catastrophe In January of 2025, UK Security recommended denying Mandelson high-level clearance given concerns over his web of contacts in China, Russia, and Israel , a £1m loan linked to an Israeli startup, and his lobbying firm Global Counsel's sticky client list . Epstein ties added "general reputational risk." Foreign Office officials overruled the recommendation the next day with scant written mitigations. Starmer claims he was never properly briefed – calling it "unforgivable." Top F...

According to an SEC filing dated May 14, 2026, Broadwood Capital purchased 1,104,351 shares of STAAR Surgical Company. (NASDAQ:STAA) during the first quarter, an estimated $21.08 million transaction based on the quarter’s average share price. The fund’s quarter-end position in STAAR Surgical decreased in value by $45.28 million, a figure that reflects both the additional shares acquired and changes in the stock price over the period. STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, leveraging proprietary lens technology to address a broad range of refractive errors. Continue reading

Nick Sargen, International Economist and Consultant, discusses the economic impact of recent global shocks and how investors should play the current market amid uncertainty. (Source: Bloomberg)

phakphum patjangkata/iStock via Getty Images Fund Overview The fund seeks to provide a high level of current income with a secondary objective of capital appreciation. It has maximum flexibility to dynamically allocate among equities, convertible bonds, fixed-income securities, and alternative investments around the world. Current Annualized Distribution Rate 8.26%* Current Annualized Distribution Rate is the Fund's most recent distribution, expressed as an annualized percentage of the Fund's current market price per share. Market Overview Global equities declined in the first quarter while trading in two distinct environments. Equities rose over the first two months as the outlook for global growth and earnings improved, only to sell off in March amid the military conflict in Iran, a spike in oil prices, and rising economic uncertainty. The broad-based MSCI ACWI Index returned -3.11% during the quarter. Developed markets returned -3.47%, as measured by the MSCI World Index, and US equities returned -4.33%, as reflected by the S&P 500 Index. Emerging markets sold off in March but led other regions in the first quarter, as the MSCI Emerging Markets Index returned -0.10%. AVERAGE ANNUAL RETURNS (%) QTD 1-YEAR 3-YEAR 5-YEAR 10-YEAR SINCE INCEPTION (6/27/07) Calamos Global Dynamic Income Fund Market Price -0.76 23.22 16.77 2.54 10.78 6.11 NAV 2.03 24.08 17.39 6.17 10.54 7.06 Click to enlarge Returns of less than 12 months are cumulative returns. Returns for periods greater than 12 months are annualized returns. Total return measures net investment income and capital gain or loss from portfolio investments as an annualized average. In calculating net investment income, all applicable fees and expenses are deducted from the returns. Performance data quoted represents past performance, which is no guarantee of future results. Current performance may be lower or higher than the performance quoted. Portfolios are managed according to their respective strategies which may dif...

Tesla sales in Portugal more than quadruple in May Yahoo Finance UK

美国总统特朗普在接受NBC新闻记者采访时表示，他尚未收到伊朗关于暂停谈判的消息。

特朗普谈及伊朗问题：说实话，我们话说得太多了。保持缄默或许才是上策。

JHVEPhoto/iStock Editorial via Getty Images L3Harris Technologies ( LHX ) said Monday it expanded its Advanced Manufacturing Facility-South in Huntsville, Alabama, through a $25 million investment that adds 130,000 square feet (12,077.4 m²) of manufacturing space. The expansion increases the company's total footprint in Huntsville to approximately 670,000 square feet (0.06 square kilometers) across three sites, according to L3Harris. The move comes as defense contractors across the United States increase production capacity in response to Pentagon efforts to replenish weapons inventories and expand manufacturing of missiles, munitions and related components. Industry executives and government officials have repeatedly cited supply-chain constraints and limited production capacity as challenges to meeting growing defense demand. For investors, Huntsville has become a focal point for defense manufacturing growth due to its concentration of missile, space and defense contractors, as well as its proximity to Redstone Arsenal and key U.S. Army and Missile Defense Agency operations. L3Harris ( LHX ) said the expanded facility will support production activities tied to its solid rocket motor programs. The company noted that Huntsville operations currently support more than half of its solid rocket motor programs through the production of inert components, with output increasing annually. "The additional space allows us to lean forward and surge capacity in a way that directly aligns with the Department of War's demand for critical munition acceleration," Ken Bedingfield, president of missile solutions at L3Harris, said in a statement. The company said the facility was able to expand using an existing building with infrastructure already in place, allowing production capacity to be added more quickly than would be possible through a new construction project. L3Harris also said it has increased its investment in Huntsville in recent years, including a threefold increase in c...

上交所公告，对邦彦技术股份有限公司有关责任人予以监管警示。经查明，邦彦技术股份有限公司（以下简称公司）存在募集资金使用未明确分级审批权限、2022 年至2025年实质性内部交易未合并抵消、2023 年内部委托研发合并抵消不规范、2024 年应收账款预期信用损失历史数据测算依据不充分、2025 年固定资产折旧分摊不准确等情形。其中，实质性内部交易未合并抵消、内部委托研发合并抵消不规范、固定资产折旧分摊不准确等事项影响了公司相关信息披露的准确性。公司时任财务总监、董事会秘书邹家瑞作为公司财务事项和信息披露事项具体负责人，未勤勉尽责，对任期内公司相关违规行为负有责任。作出如下监管措施决定：对邦彦技术股份有限公司时任财务总监、董事会秘书邹家瑞予以监管警示。

Jonathan Ferro, Lisa Abramowicz and Annmarie Hordern speak daily with leaders and decision makers from Wall Street to Washington and beyond. No other program better positions investors and executives for the trading day. (Source: Bloomberg)

In trading on Monday, the First Trust Cloud Computing ETF is outperforming other ETFs, up about 6.3% on the day. Components of that ETF showing particular strength include shares of Asana, up about 18.8% and shares of Mongodb, up about 16.4% on the day. And underperforming oth

Anthropic已向美国证券交易委员会（SEC）保密提交S-1表格注册声明草案，为拟议中的首次公开募股（IPO）做准备。 此次提交使Anthropic在SEC审核结束后拥有启动上市的选择权，拟发行股票数量尚未确定，股票发行价格区间也尚未确定，拟议中的IPO仍将取决于市场状况及其他因素。 责任编辑：李桐

History Warns Advanced Micro Devices Investors About This AOL.com

S&P 500 companies' quarterly earnings growth held steady at nearly 28% compared with financials repo

Dell stock was gaining again after it unveiled its XPS 13 laptop, a direct rival to the Apple MacBook Neo.

Nvidia Corp. is entering the PC market with a new chip aimed at loosening the stranglehold of Intel Corp. technology in that arena and modernizing the machines for the AI era. Mandeep Singh, Global Tech Research Head at Bloomberg Intelligence, discusses the move and what it means for the future of computing. (Source: Bloomberg)

Anthropic投资方股价跳涨， Zoom 通讯股价上涨 9.4%，韩国 SK 电信美股涨幅 14.6%。据悉，Anthropic秘密向美国证券交易委员会提交S-1文件草稿，筹备首次公开募股，拟发行股份的数量及发行价尚未确定。

In trading on Monday, paper & forest products shares were relative laggards, down on the day by about 2.6%. Helping drag down the group were shares of Mativ, off about 8% and shares of Mercer International down about 4.4% on the day. Also lagging the market Monday are cons

In trading on Monday, application software shares were relative leaders, up on the day by about 4.7%. Leading the group were shares of REalloys, up about 23.9% and shares of Nebius Group up about 17.5% on the day. Also showing relative strength are information technology servi

Big news in enterprise AI broke over the weekend as Chinese AI startup MiniMax released its highly anticipated M3 large language model on Sunday evening Eastern time, pairing frontier-tier coding and agentic performance with a 1-million-token context window and native multimodality for a fraction of the cost of leading proprietary models, with pricing starting at just $20 per month under its new subscription token plans. The company's leadership also announced plans to deliver the model under an open source license including "open weights," allowing for full enterprise downloading and customizability free-of-charge, coming sometime in the next 10 days. For now, it is available via the MiniMax API at a special discounted price of $0.3 per 1 million input tokens and $1.20 per million output tokens (on fresh cache) for the next week — beating proprietary U.S. giants like Google, OpenAI and Anthropic handily on cost, while also eclipsing the performance of the latest models from the former two on selected benchmarks. Even at its full price of $0.6/$2.40 per million input/output tokens, MiniMax-M3 remains at just 8-20% the cost of the leading, proprietary U.S. models. The traditional matrix governing large language model development has long dictated a rigid choice: software developers can either access top-tier closed-source intelligence behind restrictive APIs, or deploy nimble, cost-effective open models that falter on multi-step reasoning, dense coding tasks, and massive data sequences. MiniMax-M3 fundamentally upends this paradigm. By unifying these three historically separated frontier capabilities, M3 introduces a level of comprehensive utility previously restricted to expensive, closed-source ecosystems, effectively shifting the baseline of open-weights systems while drastically minimizing the operational compute footprint required to execute complex development loops. VentureBeat Frontier AI Model API Pricing Snapshot Model Input Output Total Cost Source MiMo-V2...

Micron (MU) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The company added a warning to prospective investors that a major dilution could be in the cards after it goes public.

The company added a warning to prospective investors that a major dilution could be in the cards after it goes public.

The Claude-maker is racing OpenAI and SpaceX to the public markets

libre de droit Kidney cancer patients taking AstraZeneca's ( AZN ) Imfinzi (durvalumab) in combination with Imjudo (tremelimumab), Lenvima (lenvatinib), and transarterial chemoembolization (TACE) had c linically meaningful improvement in progression-free survival vs. TACE alone. Those in active treatment arms were given the STRIDE regimen (Single Tremelimumab-actl Regular Interval Durvalumab), with or without lenvatinib, before TACE, followed by in combination with TACE. At an interim analysis, STRIDE along with lenvatinib and TACE led to a 30% reduction in the risk of disease progression or death vs. TACE alone. Median progression-free survival was 13 months for STRIDE compared to 9.8 months for TACE. A positive trend was seen in a secondary endpoint, overall survival, with STRIDE plus lenvatinib and TACE vs. TACE alone. More on AstraZeneca AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins AstraZeneca PLC (AZN) Q1 2026 Earnings Call Transcript AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold AstraZeneca wins approval of Imfinzi for additional bladder cancer type AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant

Donaldson today announced that its Board of Directors declared a regular cash dividend of 32.0 cents per share, an increase of 6.7% from the prior quarterly dividend of 30.0 cents per share. The dividend is payable June 30, 2026, to shareholders of record on June 15, 2026. Donal

Nvidia is taking on Intel and AMD with AI chip for computers East Bay Times